China’s Regulatory System Enters a New Phase of Modernization China’s pharmaceutical regulatory system is entering a new phase of accelerated modernization, creating policy driven opportunities for innovative drug development and global collaboration. The Fourth Revision of the Regulations for the Implementation of the Drug Administration Law , issued by the State Council in January 2026 and scheduled to take effect on May 15, 2026, represents the most structurally significant update in over two decades. This revision signals the clear transition of China’s pharmaceutical landscape from a "generic driven" to an "innovation driven" re gulatory paradigm.